Patient and disease characteristics (n=2740)
n | % | |
Age at diagnosis | ||
Median (mean) | 45 (43.8) | |
Range | 20–60 | |
IQR | 40–48 | |
Year of diagnosis | ||
2010 | 530 | 19.3 |
2011 | 537 | 19.6 |
2012 | 498 | 18.2 |
2013 | 597 | 21.8 |
2014 | 578 | 21.1 |
Family history* | ||
No | 1218 | 45.7 |
Yes | 1445 | 54.3 |
Unknown | 77 | |
Live children | ||
No | 749 | 27.3 |
Yes | 1991 | 72.7 |
Histology | ||
Any ductal no lobular | 2188 | 79.9 |
Any lobular no ductal | 268 | 9.8 |
Lobular and ductal | 176 | 6.4 |
Inflammatory | 12 | 0.4 |
Other | 96 | 3.5 |
Grade* | ||
G1 | 196 | 7.8 |
G2 | 631 | 25.0 |
G3 | 1694 | 67.2 |
Unknown | 219 | |
LN pos exact* | ||
No | 1746 | 63.8 |
Yes | 991 | 36.2 |
Unknown | 3 | |
Stage* | ||
I | 1377 | 54.4 |
II | 846 | 33.4 |
III | 307 | 12.2 |
Unknown | 210 | |
Chemotherapy | ||
No | 1020 | 37.2 |
Yes | 1720 | 62.8 |
HER-2 targeted therapy | ||
None | 2306 | 84.2 |
Trastuzumab | 328 | 12.0 |
Trastuzumab+other | 106 | 3.9 |
Any endocrine treatment | ||
No | 213 | 7.8 |
Yes | 2527 | 92.2 |
BSO | ||
None | 2506 | 91.5 |
Yes | 234 | 8.5 |
Medical OS | ||
None | 2458 | 89.7 |
Yes | 282 | 10.3 |
*For these variables, the unknowns are not considered in the percentage reporting.
BSO, bilateral salpingo-oophorectomy; HER-2, human epidermal growth factor receptor 2; IQR, interquartile range; LN, lymph node; OS, ovarian suppression.